# Pertuzumab (Perjeta)

Source: https://ourhealthnetwork.com/drugs/pertuzumab
Data: FDA Orange Book and OpenFDA, refreshed periodically

## What is Pertuzumab?

Pertuzumab (brand name: Perjeta) is a her2/neu receptor antagonist. It is prescribed to treat breast neoplasms.

## Brand names

Perjeta

## Indications

Pertuzumab is primarily prescribed for the treatment of breast neoplasms.

## Conditions treated

- [Breast Neoplasms](https://ourhealthnetwork.com/conditions/breast-neoplasms)

## Mechanism of action

Pertuzumab targets the extracellular dimerization domain (Subdomain II) of the human epidermal growth factor receptor 2 protein (HER2) and, thereby, blocks ligand-dependent heterodimerization of HER2 with other HER family members, including EGFR, HER3, and HER4. As a result, pertuzumab inhibits ligand-initiated intracellular signaling through two major signal pathways, mitogen-activated protein (M

## Drug classification

- Established Pharmacologic Class: HER2/neu Receptor Antagonist [EPC]
- Mechanism of Action class: HER2/Neu/cerbB2 Antagonists [MoA]
- Route of administration: INTRAVENOUS

## Common side effects

anemia, headache, vomiting

## Sources and disclaimers

- FDA Orange Book and OpenFDA dataset
- This information is for educational purposes only and does not constitute medical advice. Always consult a healthcare professional before starting, stopping, or changing any medication.

## Related

- [All drugs](https://ourhealthnetwork.com/drugs)
- [Find specialists who prescribe this drug](https://ourhealthnetwork.com/find-doctors)
- [Methodology](https://ourhealthnetwork.com/methodology)